A pioneer in applying artificial intelligence technologies to medical imaging, Median Technologies develops and markets eyonis® — a suite of AI-powered Software as a Medical Device for the early diagnosis of solid tumor cancers. The first device of the eyonis® portfolio, eyonis® LCS, is designed for lung cancer screening procedures. eyonis® LCS is currently under review for FDA 510(k) clearance in the U.S. and CE marking in Europe. In addition to its Software as a Medical Device business, Median also provides central imaging services and AI-based image analysis for oncology clinical trials in the biopharmaceutical industry through its iCRO business.